EMC6 Antibody

What is EMC6 and what is its primary cellular function?

EMC6 is a critical subunit of the endoplasmic reticulum membrane protein complex (EMC) that facilitates energy-independent insertion of newly synthesized membrane proteins into ER membranes. It preferentially accommodates proteins with transmembrane domains that are weakly hydrophobic or contain destabilizing features such as charged and aromatic residues . Functionally, EMC6 participates in both cotranslational insertion of multi-pass membrane proteins and post-translational insertion of tail-anchored proteins into ER membranes . This protein plays an important role in maintaining proper protein trafficking and ER homeostasis, with emerging evidence suggesting its involvement in autophagy regulation.

How does EMC6 expression vary across normal and cancerous tissues?

EMC6 expression demonstrates significant tissue-specific patterns with notable differences between normal and malignant states. Comprehensive bioinformatic analyses across 33 cancer types reveal that EMC6 is significantly overexpressed in most cancers compared to corresponding normal tissues, with particularly elevated levels in bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), esophageal carcinoma (ESCA), and lung adenocarcinoma (LUAD) . Notable exceptions include kidney chromophobe (KICH) and kidney renal clear cell carcinoma (KIRC), where EMC6 expression is significantly decreased . Immunohistochemical analysis from the Human Protein Atlas (HPA) database confirms significantly higher EMC6 expression in LUAD tissues compared to normal lung tissues .

What experimental approaches are most suitable for detecting EMC6 protein expression?

For EMC6 protein detection, multiple complementary techniques yield reliable results:

• Immunohistochemistry (IHC-P): Useful for tissue samples, with rabbit polyclonal antibodies targeting human EMC6 amino acids 1-50 showing specific staining patterns . Researchers should include positive controls of known EMC6-expressing tissues and negative controls omitting primary antibody.

• Immunocytochemistry/Immunofluorescence (ICC/IF): Effective for cellular localization studies in cultured cells, allowing co-localization with ER markers .

• Western blotting: Though not explicitly mentioned in the search results, this method is suitable for quantitative expression analysis using validated antibodies against EMC6.

• qPCR: Successfully used to verify EMC6 knockdown efficiency in experimental models, demonstrating utility for gene expression analysis .

When selecting a method, researchers should consider the specific research question, sample type, and required detection sensitivity.

How does EMC6 expression impact cancer patient prognosis?

EMC6 expression significantly impacts patient outcomes across multiple cancer types as demonstrated by comprehensive survival analyses:

These findings suggest EMC6 could serve as a prognostic biomarker, particularly in lung adenocarcinoma where it demonstrates the most consistent and significant associations with poor outcomes.

What molecular mechanisms underlie EMC6's role in cancer progression?

EMC6 appears to mediate cancer progression through multiple interconnected mechanisms:

These mechanisms collectively suggest EMC6 promotes cancer progression through both tumor-intrinsic effects on growth and invasion, and tumor-extrinsic effects on immune surveillance.

How can EMC6 be effectively targeted or modulated in experimental cancer models?

Based on experimental approaches described in the search results, researchers can effectively modulate EMC6 through:

• RNA Interference: Small interfering RNA (siRNA) targeting EMC6 successfully reduces expression in cancer cell lines, as validated by qPCR . When designing siRNA experiments:

  • Include multiple independent siRNA sequences to confirm specificity

  • Validate knockdown efficiency at both mRNA and protein levels

  • Use appropriate non-targeting control siRNAs

• In Vivo Modeling: Subcutaneous tumor models using EMC6-knockdown cancer cells in mice provide valuable insights into tumor growth dynamics and immune infiltration . This approach demonstrated that reducing EMC6 expression significantly:

  • Decreases tumor growth rate

  • Increases infiltration of CD4+ T cells, CD8+ T cells, and macrophages

• Cell Line Selection: Based on CCLE database analysis, A549 cells show stable and high EMC6 expression, making them a suitable model for LUAD studies .

When designing EMC6 modulation experiments, researchers should incorporate appropriate functional readouts including proliferation assays (e.g., CCK-8), invasion/migration assays (transwell, wound healing), and immune infiltration analysis as relevant to their specific research questions.

What is the relationship between EMC6 and tumor immunity?

EMC6 demonstrates complex relationships with tumor immunity that vary across cancer types:

These findings suggest EMC6 may participate in tumor immune escape mechanisms, particularly in LUAD, making it a potential target for improving immunotherapy effectiveness. The negative correlation with T cell infiltration is especially relevant given the central role of T cells in anti-tumor immunity.

How does EMC6 interact with cellular stress response pathways like ferroptosis and cuproptosis?

While the search results don't provide explicit mechanistic details, they indicate EMC6 is involved in regulating both ferroptosis and cuproptosis in lung adenocarcinoma . These emerging forms of regulated cell death are increasingly recognized as important in cancer biology:

• Ferroptosis Connection: EMC6 has been previously identified as a key gene in autophagy , and autophagy is known to regulate ferroptosis through various mechanisms. The functional analysis suggests EMC6 may influence ferroptosis sensitivity in cancer cells, potentially affecting therapeutic responses to ferroptosis inducers.

• Cuproptosis Involvement: The recent identification of cuproptosis as a copper-dependent cell death mechanism makes EMC6's involvement particularly interesting. Given EMC6's role in ER membrane protein insertion , it may influence copper transporter localization or function, thereby affecting cellular copper homeostasis and cuproptosis sensitivity.

• Integrated Stress Response: As an ER membrane protein complex component, EMC6 likely participates in the broader cellular stress response network. Previous studies indicate that "tumor cells whose ER stress were induced are able to release certain factors that promote their own growth and inhibit the function of tumor-killing immune cells" , suggesting EMC6 may link ER stress, cell death pathways, and immune evasion.

Researchers investigating these connections should consider experimental approaches like:

• Measuring ferroptosis and cuproptosis markers in EMC6-modulated cells

• Assessing sensitivity to ferroptosis and cuproptosis inducers following EMC6 manipulation

• Examining interactions between EMC6 and known regulators of these cell death pathways

What is the correlation between EMC6 expression and tumor mutational burden (TMB)?

Tumor mutational burden (TMB) represents the quantity of mutations within tumor cells and serves as an indicator of potential immune response stimulation and patient prognosis. Analysis of 33 cancer types revealed significant associations between EMC6 expression and TMB in several cancers:

• Strongest TMB Correlations: EMC6 expression strongly associates with gene mutations in:

  • Stomach adenocarcinoma (STAD)

  • Sarcoma (SARC)

  • Uterine corpus endometrial carcinoma (UCEC)

  • Lung adenocarcinoma (LUAD)

This correlation between EMC6 and TMB has important implications for understanding tumor evolution and potential immunotherapy responses. Tumors with higher TMB often show better responses to immune checkpoint inhibitors, suggesting EMC6 expression patterns might help predict immunotherapy efficacy.

The biological mechanism underlying this correlation remains to be fully elucidated but may involve:

• EMC6's role in managing ER stress caused by increased mutational load

• Effects on antigen presentation pathways that process and present mutated peptides

• Influence on DNA damage response or repair pathways

Researchers studying this relationship should consider integrating EMC6 expression data with whole-exome sequencing to calculate precise TMB scores and correlate with clinical outcomes.

What controls and validation steps are essential when using EMC6 antibodies?

When employing EMC6 antibodies for research applications, the following validation steps ensure reliable results:

• Antibody Specificity Verification:

  • Western blot analysis showing a single band at the expected molecular weight

  • Comparison with EMC6 knockout or knockdown samples as negative controls

  • Testing across multiple cell lines with known EMC6 expression levels

  • For immunohistochemistry applications, using rabbit polyclonal antibodies targeting human EMC6 amino acids 1-50 that have been validated for IHC-P applications

• Protocol Optimization:

  • Antibody titration to determine optimal concentration

  • Antigen retrieval method optimization for fixed tissues

  • Comparing different blocking solutions to minimize background

  • Testing multiple secondary antibody systems for optimal signal-to-noise ratio

• Experimental Controls:

  • Positive control: Known EMC6-expressing tissues/cells

  • Negative control: EMC6-knockdown samples or secondary-antibody-only controls

  • Isotype control: Same species antibody of irrelevant specificity

• Cross-validation:

  • Confirming protein detection with multiple independent antibodies

  • Correlating protein detection with mRNA expression data

  • Verifying subcellular localization with established ER markers

These rigorous validation steps minimize the risk of non-specific binding and false-positive results when using EMC6 antibodies for critical research applications.

How should researchers analyze discrepancies between EMC6 expression data from different experimental platforms?

When confronted with discrepancies in EMC6 expression data across different platforms, researchers should implement a systematic analytical approach:

• Platform-Specific Limitations Assessment:

  • Antibody-based methods (IHC, Western blot): Evaluate antibody specificity, epitope accessibility, and protocol differences

  • RNA-based methods (qPCR, RNA-seq): Consider primer efficiency, splice variants, and normalization procedures

  • Database mining: Examine cohort characteristics, normalization methods, and statistical thresholds

• Cross-Platform Validation Strategy:

  • Direct comparison using matched samples across platforms

  • Statistical correlation analysis between methods

  • Meta-analysis incorporating quality assessment of each dataset

• Biological Context Interpretation:

  • Consider tissue/cell type-specific expression patterns

  • Evaluate potential post-transcriptional regulation explaining RNA-protein discrepancies

  • Assess disease stage and microenvironmental factors that might influence EMC6 expression

• Resolution Approaches:

  • For antibody discrepancies: Test multiple antibodies targeting different EMC6 epitopes

  • For RNA-protein discrepancies: Investigate potential post-transcriptional or post-translational regulation

  • For cross-study inconsistencies: Stratify by relevant clinicopathological variables

The search results show that EMC6 expression has been successfully evaluated using multiple approaches, including TCGA database analysis, GEO datasets (GSE19188, GSE44077, GSE31201, jacob-00182-HLM), CCLE database for cell lines, and experimental validation using qPCR and immunohistochemistry . This multi-platform approach provides a model for comprehensive expression analysis that minimizes platform-specific biases.

What are the best experimental approaches for studying EMC6's role in specific cell death pathways?

To effectively investigate EMC6's role in regulated cell death pathways such as ferroptosis and cuproptosis, researchers should employ a multi-faceted experimental design:

• Genetic Manipulation Approaches:

  • siRNA-mediated knockdown: Successfully used in A549 cells with validation by qPCR

  • CRISPR-Cas9 knockout: For complete elimination of EMC6 function

  • Overexpression systems: To assess gain-of-function effects

  • Rescue experiments: To confirm specificity of observed phenotypes

• Cell Death Pathway-Specific Assays:

  • Ferroptosis Assessment:

    • Lipid peroxidation measurement (BODIPY-C11, MDA assays)

    • GSH depletion analysis

    • Iron chelation rescue experiments

    • Expression analysis of ferroptosis regulators (GPX4, SLC7A11)

  • Cuproptosis Assessment:

    • Intracellular copper measurement

    • Mitochondrial respiration analysis

    • Protein lipoylation status

    • Response to copper ionophores

• Mechanistic Investigation Tools:

  • Co-immunoprecipitation to identify EMC6 interaction partners

  • Proteomics analysis of EMC6-deficient cells

  • Subcellular fractionation to track localization changes

  • Metabolomics to assess pathway alterations

• In Vivo Validation:

  • Xenograft models with EMC6-modulated cancer cells, similar to the approaches used in previous studies

  • Pharmacological modulation of cell death pathways

  • Histological and immunohistochemical assessment of cell death markers

These approaches should be implemented with appropriate controls and multiple independent methods to confirm findings, as exemplified by the comprehensive approach used in previous EMC6 studies combining in vitro functional assays with in vivo models .

What therapeutic strategies targeting EMC6 show the most promise for cancer treatment?

Based on current understanding of EMC6 biology, several therapeutic approaches warrant investigation:

• Direct EMC6 Inhibition Strategies:

  • Small molecule inhibitors targeting EMC6 protein-protein interactions

  • Peptide-based disruption of EMC complex assembly

  • Antisense oligonucleotides or siRNA delivery systems to reduce EMC6 expression, building on successful knockdown approaches

• Immunotherapy Enhancement:

  • Combination approaches pairing EMC6 inhibition with immune checkpoint blockade, leveraging EMC6's negative correlation with immune cell infiltration

  • Therapeutic vaccines targeting EMC6-expressing tumor cells

  • CAR-T cell approaches with EMC6 as a target antigen in high-expressing tumors

• Cell Death Pathway Exploitation:

  • Sensitization to ferroptosis or cuproptosis inducers through EMC6 modulation

  • Combination with ER stress inducers to overwhelm adaptive capacity

  • Synthetic lethality approaches targeting EMC6-dependent cancer cells

• Biomarker Applications:

  • Patient stratification for existing therapies based on EMC6 expression

  • Monitoring treatment response and resistance development

  • Early detection approaches in high-risk populations

The experimental evidence demonstrating that EMC6 knockdown reduces tumor growth and increases immune cell infiltration in vivo provides strong rationale for therapeutic development . Priority should be given to lung adenocarcinoma applications, where EMC6's role has been most extensively characterized and where clinical need remains high.

How might EMC6's role in normal physiology inform potential side effects of therapeutic targeting?

Understanding EMC6's physiological functions helps anticipate potential adverse effects of therapeutic targeting:

• Critical Physiological Functions:

  • EMC6 enables energy-independent insertion of membrane proteins with specific characteristics into ER membranes

  • Involved in cotranslational insertion of multi-pass membrane proteins and post-translational insertion of tail-anchored proteins

  • Mediates proper N-terminal transmembrane domain insertion, controlling topology of multi-pass membrane proteins like G protein-coupled receptors

• Potential Side Effect Mechanisms:

  • Membrane Protein Processing Disruption: Therapeutic inhibition might impair processing of essential membrane proteins, affecting:

    • Neurotransmitter receptors and ion channels in neurons

    • Glucose transporters in metabolically active tissues

    • Cytokine receptors in immune cells

  • ER Stress Responses: EMC6 inhibition could trigger unfolded protein responses and ER stress in normal tissues, potentially causing:

    • Pancreatic beta cell dysfunction (diabetes risk)

    • Neuronal toxicity (cognitive effects)

    • Hepatocyte stress (liver function impairment)

  • Tissue-Specific Vulnerabilities: Based on differential expression patterns, tissues with high EMC6 dependency might show greater sensitivity to inhibition

• Risk Mitigation Strategies:

  • Targeted delivery to tumor tissues using nanoparticle formulations

  • Intermittent dosing schedules to allow recovery of normal tissues

  • Combination approaches allowing lower EMC6 inhibitor doses

  • Patient selection based on tumor/normal tissue expression ratio

While the search results don't provide comprehensive normal tissue expression data, understanding EMC6's fundamental role in membrane protein biogenesis suggests potential for broad physiological effects that must be carefully evaluated during therapeutic development.

What research questions remain unresolved regarding EMC6's molecular mechanisms?

Despite significant advances in understanding EMC6 biology, several critical questions remain unanswered:

• Structural Biology Questions:

  • What is the atomic structure of EMC6 within the EMC complex?

  • How does EMC6 recognize and facilitate insertion of specific membrane protein substrates?

  • Which domains mediate interactions with other EMC subunits and client proteins?

• Regulatory Mechanism Questions:

  • How is EMC6 expression transcriptionally and post-transcriptionally regulated?

  • What post-translational modifications affect EMC6 function?

  • How is EMC6 activity modulated in response to cellular stress conditions?

• Cancer Biology Questions:

  • What specific membrane proteins dependent on EMC6 drive cancer progression?

  • How does EMC6 mechanistically influence immune cell infiltration and function?

  • What causes the cancer type-specific differences in EMC6's correlation with immune markers?

  • What molecular mechanisms link EMC6 to ferroptosis and cuproptosis regulation?

• Therapeutic Development Questions:

  • What structures or interfaces would provide druggable targets on EMC6?

  • How might resistance to EMC6-targeted therapies develop?

  • Would EMC6 inhibition synergize with specific existing cancer therapies?

• Predictive Biomarker Questions:

  • What molecular features determine cancer cell dependency on EMC6?

  • Can EMC6 expression or modification patterns predict therapy response?

  • How does EMC6's relationship with tumor mutational burden impact immunotherapy efficacy?

Addressing these questions will require interdisciplinary approaches combining structural biology, cancer genomics, immunology, and medicinal chemistry to fully exploit EMC6's therapeutic potential while managing potential risks.

What experimental approach would yield the most comprehensive understanding of EMC6 in cancer?

Based on current knowledge gaps and successful previous approaches, an ideal experimental strategy would combine:

• Multi-omics Profiling:

  • Proteomics analysis of EMC6 interactome in normal vs. cancer cells

  • Transcriptome profiling following EMC6 modulation

  • Metabolomics to identify pathway alterations

  • Secretome analysis to identify factors mediating immune effects

• Functional Genomics:

  • CRISPR screens to identify synthetic lethal interactions with EMC6

  • Genome-wide association studies correlating EMC6 with mutation signatures

  • EMC6 structure-function analysis using domain-specific mutations

• Immunological Investigation:

  • Co-culture systems with EMC6-modulated cancer cells and immune cells

  • Cytokine/chemokine profiling following EMC6 manipulation

  • In vivo models with intact immune systems, building on previous successful approaches

• Translational Research Components:

  • Patient-derived xenografts with EMC6 modulation

  • Clinical sample analysis correlating EMC6 with treatment responses

  • Development and testing of EMC6-targeted therapeutic candidates

This comprehensive approach would build upon the successful strategies previously employed, including siRNA knockdown, in vitro functional assays, and in vivo tumor models , while extending into new areas to address remaining knowledge gaps.

How should researchers interpret conflicting findings about EMC6 across different cancer types?

When confronted with heterogeneous or conflicting findings regarding EMC6 across cancer types, researchers should:

• Consider Cancer-Specific Biology:

  • Different cellular origins and driver mutations may influence EMC6 dependency

  • Tissue-specific microenvironments might alter EMC6's role

  • Cancer stage and evolution could explain divergent findings

• Evaluate Methodological Differences:

  • Sample sizes and statistical power

  • Technical approaches and their limitations

  • Controlling for confounding variables

• Apply Integrative Analysis:

  • Multi-cancer meta-analysis with rigorous inclusion criteria

  • Molecular subtyping across traditional cancer boundaries

  • Network analysis identifying context-dependent interaction partners

• Reconciliation Strategies:

  • Identify common mechanisms across cancer types

  • Define cancer-specific pathways related to EMC6

  • Develop predictive biomarkers for EMC6 dependency

The search results illustrate this complexity, showing EMC6 is overexpressed in most cancers but underexpressed in kidney cancers , positively correlated with immune markers in some cancers but negatively in others , and associated with progression in some cancer types while showing the opposite pattern in others . These observations suggest EMC6 functions within complex cellular networks that vary by tissue context.

What quality control measures are essential when publishing EMC6 research findings?

To ensure reproducibility and reliability of EMC6 research, publications should incorporate:

• Reagent Validation and Documentation:

  • Antibody validation data including specificity controls

  • Complete sequence information for genetic constructs

  • Authentication of cell lines with STR profiling

  • Detailed protocols enabling reproducibility

• Statistical Rigor:

  • Appropriate sample sizes with power calculations

  • Correction for multiple hypothesis testing

  • Blinded analysis where applicable

  • Complete reporting of all samples, including outliers

• Biological Controls:

  • Multiple independent methods confirming key findings

  • Rescue experiments demonstrating specificity

  • Positive and negative controls for all assays

  • Demonstration of consistent results across multiple cell lines or models

• Data Transparency:

  • Deposition of raw data in appropriate repositories

  • Sharing of analytical code and custom software

  • Disclosure of all experimental conditions

  • Reporting of unsuccessful approaches or negative results

The comprehensive approach used in previous EMC6 studies provides a good model, incorporating multiple validation methods including differential expression analysis across multiple datasets, survival analyses from multiple sources, and experimental validation using both in vitro and in vivo approaches .